- Home
- GITS vs KLTO Comparison
GITS vs KLTO Comparison
Compare GITS & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- KLTO
- Stock Information
- Founded
- GITS 2018
- KLTO 2019
- Country
- GITS South Korea
- KLTO United States
- Employees
- GITS N/A
- KLTO N/A
- Industry
- GITS
- KLTO
- Sector
- GITS
- KLTO
- Exchange
- GITS Nasdaq
- KLTO NYSE
- Market Cap
- GITS 4.8M
- KLTO 5.0M
- IPO Year
- GITS N/A
- KLTO N/A
- Fundamental
- Price
- GITS $1.17
- KLTO $0.16
- Analyst Decision
- GITS
- KLTO
- Analyst Count
- GITS 0
- KLTO 0
- Target Price
- GITS N/A
- KLTO N/A
- AVG Volume (30 Days)
- GITS 86.4K
- KLTO 152.3K
- Earning Date
- GITS 11-20-2024
- KLTO 05-15-2025
- Dividend Yield
- GITS N/A
- KLTO N/A
- EPS Growth
- GITS N/A
- KLTO N/A
- EPS
- GITS N/A
- KLTO N/A
- Revenue
- GITS N/A
- KLTO N/A
- Revenue This Year
- GITS N/A
- KLTO N/A
- Revenue Next Year
- GITS N/A
- KLTO N/A
- P/E Ratio
- GITS N/A
- KLTO N/A
- Revenue Growth
- GITS 85.47
- KLTO N/A
- 52 Week Low
- GITS $0.10
- KLTO $0.11
- 52 Week High
- GITS $5.06
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- KLTO N/A
- Support Level
- GITS N/A
- KLTO N/A
- Resistance Level
- GITS N/A
- KLTO N/A
- Average True Range (ATR)
- GITS 0.00
- KLTO 0.00
- MACD
- GITS 0.00
- KLTO 0.00
- Stochastic Oscillator
- GITS 0.00
- KLTO 0.00
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.